Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 38176 | 16.5 |
09:34 ET | 13600 | 16.38 |
09:36 ET | 11622 | 16.41 |
09:38 ET | 6176 | 16.425 |
09:39 ET | 21796 | 16.5352 |
09:41 ET | 13088 | 16.5506 |
09:43 ET | 3346 | 16.6108 |
09:45 ET | 3813 | 16.61 |
09:48 ET | 6164 | 16.66 |
09:50 ET | 24015 | 16.68 |
09:52 ET | 7405 | 16.69 |
09:54 ET | 8173 | 16.674 |
09:56 ET | 30724 | 16.78 |
09:57 ET | 11901 | 16.8 |
09:59 ET | 15757 | 16.74 |
10:01 ET | 5226 | 16.73 |
10:03 ET | 3335 | 16.7999 |
10:06 ET | 1833 | 16.79 |
10:08 ET | 7053 | 16.785 |
10:10 ET | 11107 | 16.8792 |
10:12 ET | 22572 | 16.915 |
10:14 ET | 10452 | 16.87 |
10:15 ET | 3933 | 16.85 |
10:17 ET | 9278 | 16.7561 |
10:19 ET | 9944 | 16.71 |
10:21 ET | 11813 | 16.72 |
10:24 ET | 11061 | 16.75 |
10:26 ET | 3709 | 16.75 |
10:28 ET | 3517 | 16.695 |
10:30 ET | 219 | 16.72 |
10:32 ET | 5562 | 16.67 |
10:33 ET | 1682 | 16.66 |
10:35 ET | 2400 | 16.6 |
10:37 ET | 3300 | 16.58 |
10:39 ET | 5388 | 16.495 |
10:42 ET | 8066 | 16.48 |
10:44 ET | 7489 | 16.5 |
10:46 ET | 4781 | 16.48 |
10:48 ET | 941 | 16.49 |
10:50 ET | 4950 | 16.51 |
10:51 ET | 6848 | 16.475 |
10:53 ET | 1200 | 16.5 |
10:55 ET | 1914 | 16.49 |
10:57 ET | 750 | 16.47 |
11:00 ET | 1678 | 16.45 |
11:02 ET | 10513 | 16.45 |
11:04 ET | 1646 | 16.46 |
11:06 ET | 328 | 16.4674 |
11:08 ET | 2416 | 16.44 |
11:09 ET | 415 | 16.445 |
11:11 ET | 1136 | 16.44 |
11:13 ET | 500 | 16.44 |
11:15 ET | 400 | 16.45 |
11:18 ET | 300 | 16.47 |
11:20 ET | 1915 | 16.43 |
11:22 ET | 700 | 16.44 |
11:24 ET | 1149 | 16.44 |
11:26 ET | 4721 | 16.4 |
11:27 ET | 1150 | 16.42 |
11:29 ET | 3900 | 16.43 |
11:31 ET | 6040 | 16.45 |
11:33 ET | 1600 | 16.45 |
11:36 ET | 1529 | 16.45 |
11:38 ET | 100 | 16.44 |
11:40 ET | 14505 | 16.455 |
11:42 ET | 5434 | 16.47 |
11:44 ET | 700 | 16.47 |
11:45 ET | 100 | 16.46 |
11:47 ET | 1106 | 16.47 |
11:49 ET | 1003 | 16.45 |
11:51 ET | 1672 | 16.465 |
11:54 ET | 9017 | 16.45 |
11:56 ET | 4228 | 16.445 |
11:58 ET | 11326 | 16.44 |
12:00 ET | 400 | 16.445 |
12:02 ET | 850 | 16.45 |
12:03 ET | 1359 | 16.44 |
12:05 ET | 790 | 16.43 |
12:07 ET | 2200 | 16.42 |
12:09 ET | 8423 | 16.43 |
12:12 ET | 3197 | 16.415 |
12:14 ET | 1267 | 16.4 |
12:16 ET | 900 | 16.4 |
12:18 ET | 1200 | 16.39 |
12:20 ET | 2836 | 16.42 |
12:21 ET | 4522 | 16.39 |
12:23 ET | 3010 | 16.4 |
12:25 ET | 900 | 16.41 |
12:27 ET | 7333 | 16.42 |
12:30 ET | 3173 | 16.4032 |
12:32 ET | 13348 | 16.37 |
12:34 ET | 26291 | 16.335 |
12:36 ET | 8127 | 16.31 |
12:38 ET | 20999 | 16.261 |
12:39 ET | 1973 | 16.26 |
12:41 ET | 4804 | 16.265 |
12:43 ET | 6298 | 16.25 |
12:45 ET | 3255 | 16.2333 |
12:48 ET | 30898 | 16.22 |
12:50 ET | 2569 | 16.245 |
12:52 ET | 21735 | 16.19 |
12:54 ET | 5140 | 16.25 |
12:56 ET | 10710 | 16.22 |
12:57 ET | 2300 | 16.2696 |
12:59 ET | 14443 | 16.28 |
01:01 ET | 214600 | 16.295 |
01:03 ET | 3100 | 16.28 |
01:06 ET | 3579 | 16.2635 |
01:08 ET | 2781 | 16.24 |
01:10 ET | 200 | 16.235 |
01:12 ET | 2999 | 16.22 |
01:14 ET | 7488 | 16.29 |
01:15 ET | 400 | 16.29 |
01:17 ET | 600 | 16.29 |
01:19 ET | 773 | 16.29 |
01:21 ET | 650 | 16.29 |
01:24 ET | 865 | 16.305 |
01:26 ET | 200 | 16.32 |
01:28 ET | 8734 | 16.3 |
01:30 ET | 521 | 16.29 |
01:32 ET | 400 | 16.29 |
01:33 ET | 400 | 16.3 |
01:35 ET | 1200 | 16.3 |
01:37 ET | 5663 | 16.27 |
01:39 ET | 5548 | 16.28 |
01:42 ET | 11749 | 16.26 |
01:44 ET | 5004 | 16.279 |
01:46 ET | 2742 | 16.25 |
01:48 ET | 2315 | 16.255 |
01:50 ET | 2200 | 16.26 |
01:51 ET | 21548 | 16.18 |
01:53 ET | 1500 | 16.18 |
01:55 ET | 18684 | 16.16 |
01:57 ET | 9923 | 16.17 |
02:00 ET | 2339 | 16.1699 |
02:02 ET | 17913 | 16.165 |
02:04 ET | 8542 | 16.16 |
02:06 ET | 9186 | 16.13 |
02:08 ET | 1122 | 16.12 |
02:09 ET | 11869 | 16.09 |
02:11 ET | 18221 | 16.05 |
02:13 ET | 10430 | 16.0571 |
02:15 ET | 1050 | 16.0636 |
02:18 ET | 2935 | 16.065 |
02:20 ET | 2260 | 16.1 |
02:22 ET | 467 | 16.08 |
02:24 ET | 22201 | 16.07 |
02:26 ET | 1963 | 16.035 |
02:27 ET | 3521 | 16.05 |
02:29 ET | 69679 | 16.005 |
02:31 ET | 6828 | 16 |
02:33 ET | 18413 | 15.965 |
02:36 ET | 16162 | 15.92 |
02:38 ET | 12380 | 15.92 |
02:40 ET | 3173 | 16 |
02:42 ET | 2900 | 16.025 |
02:44 ET | 4750 | 15.97 |
02:45 ET | 2430 | 15.94 |
02:47 ET | 9418 | 15.95 |
02:49 ET | 692 | 15.9565 |
02:51 ET | 2343 | 15.92 |
02:54 ET | 2248 | 15.89 |
02:56 ET | 8552 | 15.89 |
02:58 ET | 18030 | 15.935 |
03:00 ET | 8346 | 15.945 |
03:02 ET | 2051 | 15.92 |
03:03 ET | 12300 | 15.915 |
03:05 ET | 700 | 15.91 |
03:07 ET | 3468 | 15.94 |
03:09 ET | 10685 | 15.91 |
03:12 ET | 1263 | 15.91 |
03:14 ET | 1478 | 15.92 |
03:16 ET | 2981 | 15.91 |
03:18 ET | 4847 | 15.92 |
03:20 ET | 2190 | 15.905 |
03:21 ET | 13736 | 15.95 |
03:23 ET | 14200 | 15.96 |
03:25 ET | 8668 | 15.95 |
03:27 ET | 10479 | 15.99 |
03:30 ET | 6626 | 15.99 |
03:32 ET | 1900 | 15.975 |
03:34 ET | 2416 | 15.975 |
03:36 ET | 5653 | 15.965 |
03:38 ET | 10328 | 15.94 |
03:39 ET | 34506 | 15.94 |
03:41 ET | 24936 | 15.88 |
03:43 ET | 66930 | 15.81 |
03:45 ET | 22990 | 15.78 |
03:48 ET | 30422 | 15.815 |
03:50 ET | 17124 | 15.835 |
03:52 ET | 30273 | 15.845 |
03:54 ET | 26479 | 15.835 |
03:56 ET | 26371 | 15.895 |
03:57 ET | 42653 | 15.83 |
03:59 ET | 91404 | 15.81 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 2.5B | 71.7x | --- |
Twist Bioscience Corp | 2.4B | -15.8x | --- |
Arrowhead Pharmaceuticals Inc | 2.9B | -5.8x | --- |
Vericel Corp | 2.3B | 4,791.8x | --- |
ADMA Biologics Inc | 2.2B | -518.6x | --- |
Maravai LifeSciences Holdings Inc | 2.2B | -8.5x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5B |
---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.30 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 71.7x |
Price/Sales (TTM) | 8.7 |
Price/Cash Flow (TTM) | 60.9x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.